Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Maria Sabater-Lleal et al, published in JTH:
“This is a very complete review of a very important field, explaining how genome-wide analyses are unraveling the genetic architecture responsible for the levels of the main cellular and plasma factors that regulate coagulation and fibrinolysis.
The authors combine this with a brief look at global coagulation tests, all this in the context of how multiple gene variants influence venous and arterial thrombosis.
Step by step we are approaching the day when whole genome sequencing will become the norm and a prerequisite for personalized medicine.
In my own field of inherited platelet disorders and in particular Glanzmann thrombasthenia, the polygenic scores of gene variants either favoring or protecting from excessive and frequent mucocutaneous bleeding should help select patients most apt for gene therapy or to receive new generation long-term prophylaxis designed to upgrade fibrin formation at sites of bleeding.
For the latter, determining the therapy dose will be crucial in assuring safety.
This review is highly recommended for all in the coagulation and hemostasis fields.”
Title: Historical review: more than two decades understanding the genetic architecture of hemostasis and thrombosis
Authors: Maria Sabater-Lleal, Florian Thibord, Paul S de Vries, Jennifer Huffman, Alisa S Wolberg, Charles J Lowenstein, Alanna C Morrison, Andrew D Johnson, Nicholas L Smith
Read the Full Article on JTH
Other articles featuring Alan Nurden on Hemostasis Today.
-
Jun 24, 2026, 16:40William Wallace: Vitamin C and Collagen Work as One Biological System
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss